{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:44Z","timestamp":1780791104275,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.arteri.2024.500755","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T07:05:42Z","timestamp":1737788742000},"page":"500755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eficacia y seguridad de los inhibidores de la PCSK9 en la vida real"],"prefix":"10.1016","volume":"37","author":[{"given":"Ant\u00f3n","family":"Gonz\u00e1lez-Guerrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Navarrete-Rouco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Benaiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Giralt-Steinhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Recasens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2024.500755_bib0235","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.500755_bib0240","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.500755_bib0245","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2024.500755_bib0250","first-page":"10","article-title":"Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey [Article in English, Spanish]","volume":"34","author":"Guijarro","year":"2022","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.500755_bib0255","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.arteri.2024.500755_bib0260","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12944-024-02283-x","article-title":"PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention","volume":"23","author":"Marco-Bened\u00ed","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.arteri.2024.500755_bib0265","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.500755_bib0270","article-title":"Strategies to improve cardiovascular health and treatment of dyslipidemia in Spain. Expert Insights Project [Article in English, Spanish]","volume":"S0214\u20139168","author":"Pedro-Botet","year":"2024","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.500755_bib0275","unstructured":"Informe de posicionamiento terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia. IPT, 12\/2020.V2. Ministerio de Sanidad\/Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. 21\/octubre\/2020 [consultado 26 Ago 2024] Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_12-2020-evolocumab-Repatha.pdf"},{"key":"10.1016\/j.arteri.2024.500755_bib0280","unstructured":"Informe de posicionamiento terap\u00e9utico de alirocumab (Praluent\u00ae) en hipercolesterolemia. IPT, 13\/2020.V2. Ministerio de Sanidad\/Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. 21\/octubre\/2020 [consultado 26 Ago 2024] Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_13-2020-alirocumab-Praluent.pdf"},{"key":"10.1016\/j.arteri.2024.500755_bib0285","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/1403494819869816","article-title":"CVD risk factors and surrogate markers - Urban-rural differences","volume":"48","author":"Nuotio","year":"2020","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.arteri.2024.500755_bib0290","first-page":"219","article-title":"Hypercholesterolaemia control in Spain: The same situation with different regional realities","volume":"35","author":"Pedro-Botet","year":"2023","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.500755_bib0295","doi-asserted-by":"crossref","first-page":"e011246","DOI":"10.1161\/JAHA.118.011246","article-title":"PCSK9 inhibitor use in the real world: Data from the National Patient-Centered Research Network","volume":"8","author":"Chamberlain","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2024.500755_bib0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-021-01283-w","article-title":"Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus","volume":"20","author":"Fischer","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arteri.2024.500755_bib0305","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11883-022-01008-8","article-title":"PCSK9 inhibitors in real-world practice: Analysis of data from 314 patients and 2 years of experience in a center of preventive cardiology","volume":"24","author":"Altschmiedov\u00e1","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.arteri.2024.500755_bib0310","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.3390\/jcm13154543","article-title":"Monoclonal anti-PCSK9 antibodies: Real-world data","volume":"13","author":"Guidotti","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.arteri.2024.500755_bib0315","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.semerg.2021.03.008","article-title":"Real-life efficacy and safety of PCSK9 inhibitors treatment: experience in three hospitals in Asturias [Article in Spanish]","volume":"47","author":"Rodr\u00edguez Escobedo","year":"2021","journal-title":"Semergen"},{"key":"10.1016\/j.arteri.2024.500755_bib0320","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.recesp.2019.03.019","article-title":"Initial real-world experience with PCSK-9 inhibitors in current indications for reimbursement in Spain","volume":"72","author":"Cordero","year":"2019","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.arteri.2024.500755_bib0325","first-page":"231","article-title":"Primer registro nacional sobre la efectividad y seguridad de evolocumab en la pr\u00e1ctica cl\u00ednica en pacientes atendidos en cardiolog\u00eda en Espa\u00f1a. Estudio RETOSS-CARDIO","volume":"32","author":"Barrios","year":"2020","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.500755_bib0330","first-page":"263","article-title":"Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study","volume":"35","author":"Blanco Echevarr\u00eda","year":"2023","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.500755_bib0335","first-page":"778","article-title":"Real-world data on comparison of lipid-lowering effects between alirocumab and evolocumab in patients with hypercholesterolemia","volume":"38","author":"Lin","year":"2022","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.arteri.2024.500755_bib0340","doi-asserted-by":"crossref","first-page":"112519","DOI":"10.1016\/j.biopha.2021.112519","article-title":"PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort","volume":"146","author":"Vicente-Valor","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.arteri.2024.500755_bib0345","unstructured":"Dictamen de la Comissi\u00f3 Farmacoterap\u00e8utica de la Medicaci\u00f3 Hospital\u00e0ria de Dispensaci\u00f3 Ambulat\u00f2ria sobre l\u2019\u00fas d\u2019alirocumab per al tractament de pacients adults amb hipercolesterol\u00e8mia prim\u00e0ria (familiar heterozig\u00f2tica i no familiar) o dislipid\u00e8mia mixta. Barcelona. Servei Catal\u00e0 de la Salut. Departament de Salut. Generalitat de Catalunya; 2017 [consultado 26 Ago 2024] Disponible en: http:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/alirocumab\/Dictamen-PHMHDA-alirocumab.pdf"},{"key":"10.1016\/j.arteri.2024.500755_bib0350","unstructured":"Dictamen de la Comissi\u00f3 Farmacoterap\u00e8utica de la Medicaci\u00f3 Hospital\u00e0ria de Dispensaci\u00f3 Ambulat\u00f2ria sobre l\u2019\u00fas d\u2019evolocumab per al tractament de pacients adults amb hipercolesterol\u00e8mia prim\u00e0ria (familiar heterozig\u00f2tica i no familiar) o dislipid\u00e8mia mixta i el tractament de pacients adults amb hipercolesterol\u00e8mia familiar homozig\u00f2tica. Barcelona. Servei Catal\u00e0 de la Salut. Departament de Salut. Generalitat de Catalunya; 2017[consultado 26 Ago 2024] Disponible en: http:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/harmonitzacio\/informes\/evolocumab\/Dictamen-PHMHDA-evolocumab.pdf"},{"key":"10.1016\/j.arteri.2024.500755_bib0355","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.03.002","article-title":"Should the \u201chigh-intensity cholesterol-lowering therapy\u201d strategy replace the \u201chigh-intensity statin therapy\u201d?","volume":"240","author":"Masana","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.500755_bib0360","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: A meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.500755_bib0365","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.arteri.2024.500755_bib0370","first-page":"26","article-title":"Criteria for referring patients to Spanish Atherosclerosis Society lipid units [Article in English, Spanish]","volume":"31","author":"S\u00e1nchez-Chaparro","year":"2019","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.500755_bib0375","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.500755_bib0380","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Longterm evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.500755_bib0385","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehad446","article-title":"Eliminating atherosclerotic cardiovascular disease residual risk","volume":"44","author":"Makover","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.500755_bib0390","doi-asserted-by":"crossref","first-page":"108717","DOI":"10.1016\/j.abb.2020.108717","article-title":"PCSK9: associated with cardiac diseases and their risk factors?","volume":"704","author":"Guo","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.arteri.2024.500755_bib0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.numecd.2023.09.023","article-title":"LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender bias","volume":"34","author":"Berteotti","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2024.500755_bib0400","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jacc.2022.10.023","article-title":"Sex disparities in familial hypercholesterolemia","volume":"81","author":"Jim\u00e9nez","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.500755_bib0405","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1093\/eurheartj\/ehae417","article-title":"Sex differences in treatment of familial hypercholesterolaemia: A meta-analysis","volume":"45","author":"Iatan","year":"2024","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2024.500755_bib0410","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.500755_bib0415","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9 - Impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.arteri.2024.500755_bib0420","doi-asserted-by":"crossref","first-page":"e010498","DOI":"10.1161\/JAHA.118.010498","article-title":"Gender differences in patient-reported outcomes among adults with atherosclerotic cardiovascular disease","volume":"7","author":"Okunrintemi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2024.500755_bib0425","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid lowering therapy and circulating PCSK9 concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.arteri.2024.500755_bib0430","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.500755_bib0435","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.arteri.2024.500755_bib0440","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FJC.0000000000001205","article-title":"Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: The LIPID-REAL registry","volume":"79","author":"Cordero","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.arteri.2024.500755_bib0445","doi-asserted-by":"crossref","first-page":"117108","DOI":"10.1016\/j.atherosclerosis.2023.03.013","article-title":"Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry","volume":"384","author":"Galema-Boers","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.500755_bib0450","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.arteri.2024.500755_bib0455","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s42003-024-06674-9","article-title":"Contrasting effects of intracellular and extracellular human PCSK9 on inflammation, lipid alteration and cell death","volume":"7","author":"Ghalali","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.arteri.2024.500755_bib0460","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3892\/mmr.2021.11970","article-title":"Cigarette smoke extract stimulates PCSK9 production in HepG2 cells via ROS\/NF-\u03baB signaling","volume":"23","author":"Ma","year":"2021","journal-title":"Mol Med Rep"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916824001219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916824001219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:38:43Z","timestamp":1758148723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916824001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0214916824001219"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2024.500755","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficacia y seguridad de los inhibidores de la PCSK9 en la vida real","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2024.500755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500755"}}